{"id":"mvc-cov1901-6-months","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:07:32.201463","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant spike protein (S-2P) produced in mammalian cells, formulated with an aluminum adjuvant to enhance immunogenicity. It is designed to elicit both humoral (antibody) and cellular (T-cell) immune responses against the coronavirus spike protein, thereby providing protection against SARS-CoV-2 infection and severe disease.","oneSentence":"MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:20.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT05097053","phase":"PHASE4","title":"A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19","status":"UNKNOWN","sponsor":"Taoyuan General Hospital","startDate":"2021-10-07","conditions":"COVID-19 Vaccine","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2025 Dec","pmid":"40955097","title":"Longitudinal dynamics of humoral immune responses following serial COVID-19 vaccinations and breakthrough infections in dialysis patients.","journal":"Human vaccines & immunotherapeutics"},{"date":"2024","pmid":"38528666","title":"An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents.","journal":"Recent patents on biotechnology"},{"date":"2022 Aug","pmid":"35579840","title":"Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.","journal":"Infectious diseases and therapy"},{"date":"2021 Dec","pmid":"34655522","title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.","journal":"The Lancet. Respiratory medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MVC-COV1901(6 Months)","genericName":"MVC-COV1901(6 Months)","companyName":"Taoyuan General Hospital","companyId":"taoyuan-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}